Movement Alert｜GENSCRIPT BIO Falls 3.44% in Regular Trading, Proposed ProBio Spin-Off Continues to Weigh on Sentiment

Market Focus

Yesterday

On September 10, GENSCRIPT BIO fell 3.44% in regular trading, trading at 32.52 HKD/share, with turnover of approximately 78.85 million HKD.

The decline extends the volatile pattern triggered by the company's September 4 announcement to spin off its indirect non-wholly owned subsidiary ProBio Technology for an independent listing on the HKEX main board. ProBio operates the group's biologics and advanced therapy CDMO services. On the announcement date, the stock plunged nearly 13%, followed by a rebound of over 8% on September 8, and subsequent pullbacks on September 9 and 10, reflecting persistent market divergence over the spin-off's impact.

The HKEX Listing Committee confirmed on August 14 that the company may proceed with the proposed spin-off. Post-completion, GENSCRIPT BIO will retain a controlling stake and continue to consolidate ProBio's financials. Some analysts have noted the spin-off could help alleviate approximately $473 million in redemption pressure arising from ProBio's preferred share agreements, though investor concerns over near-term valuation dilution appear to persist.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigreclipse.com/news/1144868845"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1144868845\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1144868845?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-10 09:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1144868845","market":"us","top_or_hot":-1,"title":"Movement Alert｜GENSCRIPT BIO Falls 3.44% in Regular Trading, Proposed ProBio Spin-Off Continues to Weigh on Sentiment","media":"Market Focus","content":"<p><p>On September 10, GENSCRIPT BIO fell 3.44% in regular trading, trading at 32.52 HKD/share, with turnover of approximately 78.85 million HKD.</p><p>The decline extends the volatile pattern triggered by the company's September 4 announcement to spin off its indirect non-wholly owned subsidiary ProBio Technology for an independent listing on the HKEX main board. ProBio operates the group's biologics and advanced therapy CDMO services. On the announcement date, the stock plunged nearly 13%, followed by a rebound of over 8% on September 8, and subsequent pullbacks on September 9 and 10, reflecting persistent market divergence over the spin-off's impact.</p><p>The HKEX Listing Committee confirmed on August 14 that the company may proceed with the proposed spin-off. Post-completion, GENSCRIPT BIO will retain a controlling stake and continue to consolidate ProBio's financials. Some analysts have noted the spin-off could help alleviate approximately $473 million in redemption pressure arising from ProBio's preferred share agreements, though investor concerns over near-term valuation dilution appear to persist.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜GENSCRIPT BIO Falls 3.44% in Regular Trading, Proposed ProBio Spin-Off Continues to Weigh on Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜GENSCRIPT BIO Falls 3.44% in Regular Trading, Proposed ProBio Spin-Off Continues to Weigh on Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-10 09:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 10, GENSCRIPT BIO fell 3.44% in regular trading, trading at 32.52 HKD/share, with turnover of approximately 78.85 million HKD.</p><p>The decline extends the volatile pattern triggered by the company's September 4 announcement to spin off its indirect non-wholly owned subsidiary ProBio Technology for an independent listing on the HKEX main board. ProBio operates the group's biologics and advanced therapy CDMO services. On the announcement date, the stock plunged nearly 13%, followed by a rebound of over 8% on September 8, and subsequent pullbacks on September 9 and 10, reflecting persistent market divergence over the spin-off's impact.</p><p>The HKEX Listing Committee confirmed on August 14 that the company may proceed with the proposed spin-off. Post-completion, GENSCRIPT BIO will retain a controlling stake and continue to consolidate ProBio's financials. Some analysts have noted the spin-off could help alleviate approximately $473 million in redemption pressure arising from ProBio's preferred share agreements, though investor concerns over near-term valuation dilution appear to persist.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01548","symbol_name":"金斯瑞生物科技","start_time":0,"source_url":"","article_id":"1144868845","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1144868845","pubTimestamp":1789004787,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 10, GENSCRIPT BIO fell 3.44% in regular trading, trading at 32.52 HKD/share, with turnover of approximately 78.85 million HKD.The decline extends the volatile pattern triggered by the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01548":"金斯瑞生物科技"},"translate_title":"走势警报|金斯瑞生物在常规交易中下跌 3.44%，拟议的 ProBio 分拆继续打压市场情绪","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":1},"content_text":"On September 10, GENSCRIPT BIO fell 3.44% in regular trading, trading at 32.52 HKD/share, with turnover of approximately 78.85 million HKD.The decline extends the volatile pattern triggered by the company's September 4 announcement to spin off its indirect non-wholly owned subsidiary ProBio Technology for an independent listing on the HKEX main board. ProBio operates the group's biologics and advanced therapy CDMO services. On the announcement date, the stock plunged nearly 13%, followed by a rebound of over 8% on September 8, and subsequent pullbacks on September 9 and 10, reflecting persistent market divergence over the spin-off's impact.The HKEX Listing Committee confirmed on August 14 that the company may proceed with the proposed spin-off. Post-completion, GENSCRIPT BIO will retain a controlling stake and continue to consolidate ProBio's financials. Some analysts have noted the spin-off could help alleviate approximately $473 million in redemption pressure arising from ProBio's preferred share agreements, though investor concerns over near-term valuation dilution appear to persist.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}